OncoCyte
OncoCyte Corporation is a biotechnology company dedicated to the development and commercialization of innovative, non-invasive diagnostics for early cancer detection. Founded in 2009 and headquartered in Irvine, California, the company specializes in laboratory-developed tests, including DetermaRx, a molecular test for early-stage adenocarcinoma of the lung, and DetermaIO, a gene expression-based test. It also focuses on DetermaDx, a blood-based test for lung cancer detection, and is working on diagnostics for bladder and breast cancers. OncoCyte aims to provide actionable insights to healthcare providers and patients, enhancing decision-making in cancer care while striving to improve patient outcomes and lower healthcare costs. The company has formed strategic collaborations to facilitate comprehensive solutions for pharmaceutical clients, encompassing patient recruitment and regulatory approvals.
Chronix Biomedical
Acquisition in 2021
Chronix Biomedical, Inc. is a molecular diagnostics company that specializes in developing laboratory-developed tests, specifically blood tests known as liquid biopsies for cancer and organ transplants. Founded in 1997 and headquartered in San Jose, California, Chronix focuses on therapy monitoring for patients undergoing chemotherapy or immunotherapy, as well as relapse monitoring post-tumor resection. Among its notable products are the CNI Monitor, which assesses the effectiveness of cancer therapies, and the Transplant Monitor, which quantifies transplant-specific DNA in plasma to detect organ rejection early. The company employs proprietary technology to analyze circulating nucleic acids in the blood, enabling healthcare professionals to monitor various chronic diseases and conditions effectively. Chronix also operates research facilities in Brookings, South Dakota, and Göttingen, Germany, and aims to collaborate with partners to further develop its innovative DNA-based assays.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.